Metabolism of MK-0524, a prostaglandin D2 receptor 1 antagonist, in microsomes and hepatocytes from preclinical species and humans

Drug Metabolism and Disposition

Volumn 35, Issue 2, 2007, Pages 283-292

  Dean, Brian J ^a   Chang, Steve ^a   Elipe, Maria Victoria Silva ^a   Xia, Yuan Qing ^a   Braun, Matt ^a   Soli, Eric ^a   Zhao, Yuming ^a   Franklin, Ronald B ^a   Karanam, Bindhu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROBENZYL) 7 FLUORO 5 (METHYLSULFONYL) 1,2,3,4 TETRAHYDROCYCLOPENTA[B]INDOL 3 YL ACETIC ACID; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MK 0524; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DOG; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME MECHANISM; HUMAN; HUMAN CELL; HYDROXYLATION; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MICROSOME; MONKEY; NONHUMAN; PRIORITY JOURNAL; RADIOCHROMATOGRAPHY; RAT; SPECIES COMPARISON;

ANIMALS; CHROMATOGRAPHY, LIQUID; DOGS; GLUCURONIDES; HEPATOCYTES; HUMANS; INDOLES; MACACA MULATTA; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROSOMES, LIVER; NADP; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN;

CANIS FAMILIARIS; MACACA FASCICULARIS; RATTUS;

EID: 33846455071     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011551     Document Type: Article

References (19)

1. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, and Jansen PL (1994) Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269:17960-17964.
2. Burchell B, Brierley CH, and Rance D (1995) Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 57:1819-1831.
3. Chang S, Reddy V, Pereira T, Dean B, Franklin R, and Karanam B (2006) The pharmacokinetics and disposition of MK-0524 a DP1 antagonist, in rats, dogs and monkeys. Xenobiotica, in press.
4. Cheng K, Wu T-J, Wu KK, Sturino C, Metters K, Gottesdiener K, Wright SD, Wang Z, O'Neill G, Lai E, et al. (2006) Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA 103:6682-6687.
5. Coffman BL, Rios GR, King CD, and Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1-4.
6. Eklund B, Kaijser L, Nowak J, and Wennmalm A (1979) Prostaglandins contribute to the vasodilation induced by nicotinic acid. Prostaglandins 17:821-830.
7. Gentile S, Rubba P, Persico M, Bronzino P, Marmo R, and Faccenda F (1985) Improvement of the nicotinic acid test in the diagnosis of Gilbert's syndrome by pretreatment with indomethacin. Hepatogastroenterology 32:267-269.
8. Jin C, Miners JO, Lillywhite KJ, and Mackenzie PI (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol Exp Ther 264:475-479.
9. King C, Tang W, Ngui J, Tephly T, and Braun M (2001) Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci 61:49-53.
10. Knoop RH (1999) Drug treatment of lipid disorders. N Engl J Med 341:498-511.
11. Luukkanen L, Mikkola J, Forsman T, Taavitsainen P, and Elovaara E (2001) Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue. Drug Metab Dispos 29:1096-1101.
12. Morrow JD, Awad JA, Oates JA, Roberts LJ 2nd (1992) Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Investig Dermatol 98:812-815.
13. Nicoll-Griffith DA, Seto C, Aubin Y, Lévesque J-F, Chauret N, Day S, Silva JM, Trimble LA, Truchon JF, Bertelette C, et al. (2006) In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorg Med Chem Lettjavascript: AL get(this, 'jour', 'Bioorg Med Chem Lett.');, in press.
14. Remmel RP and Burchell B (1993) Validation and use of cloned, expressed human drug metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions. Biochem Pharmacol 46:559-566.
15. Rubenfire M (2004) Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the impact of medical subspeciality on patient compliance to treatment (IMPACT) study. Am J Cardiol 94:306-311.
16. Shepherd J, Packard DJ, Patsch JR, Gotto AM Jr, and Taunton OD (1979) Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Investig 63:858-867.
17. Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, et al. (2006) Discovery of a potent and selective PGD2 receptor antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)- 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem, in press.
18. Vogt A, Kassner U, Hostalek U, and Steinhagen-Thiessen E (2006) On behalf of the Nautilus Study Group, 2006. Evaluation of safety and tolerability of prolonged-release nicotonic acid in a usual care setting. Curr Med Res Opin 22:417-425.
19. Zhao X-Q, Morse JS, Dowdy AA, Heise N, DeAngelis D, Frohlich J, Chait A, Albers JJ, and Brown BG (2004) Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study). Am J Cardiol 93:307-312.